CMMI
-
AMP is WAC — 10/03/25
Read more: AMP is WAC — 10/03/25Round ’em up. The Presidential priorities that have everything and nothing to do with each other. This week has been a healthcare whirlwind. Here’s what I think you need to know * Most favored nation policy is still kicking around and the company announcements are interesting, but I want to poke around under the hood…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Reference Pricing, Supply Chain, Utilization ManagementAMP is WAC — 9/12/25
Read more: AMP is WAC — 9/12/25On one hand, a busy week in the world of health policy. The quicksand of news in 2025 is real so I do my best to sidestep some news (MAHA report) to dive into the things that I think are important for my clients – including expected premium spikes, 340B rebate backlash and Medicare changes.…
-
AMP is WAC — 8/29/25
Read more: AMP is WAC — 8/29/25It felt like a relatively quiet week. Or did I just completely jinx today? Caught my Eye Ask Me Anything. FAQs released on the 340B Model Pilot program. This is the program where manufacturers with 2026 Medicare negotiated drugs can move to a rebate program for 340B for the negotiated drugs. Manufacturers that submit plans…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
340B, Biosimilars, CMMI, Drug Prices, Generics, Healthcare Costs, Importation, Insulin, Medicaid, Pharmacy Benefit ManagersDon’t Call it a Comeback
Read more: Don’t Call it a ComebackLet’s wrap up my musings on the President’s Executive Order (EO). Medicaid. Section 6 of the EO directs the Office of Management and Budget (OMB) Director, the Assistant to the President for Domestic Policy, and the Assistant to the President for Economic Policy, in coordination with the Secretary of Health and Human Services (HHS), to…
-
Caught my eye — 5/2/25
Read more: Caught my eye — 5/2/25It has been a week that has rushed by and yet Monday feels like very long time ago. You know these kinds of weeks. So, let’s do a quick roundup of what made me pause between the stimulation overload of Vegas. And So it Begins? The Food and Drug Administration (FDA) has suffered huge staffing…
-
Catch as Catch Can
Read more: Catch as Catch CanSection 4 of the President’s Executive Order (EO) on drug pricing aims to reduce the high-cost drugs for seniors through the development and implementation of a payment model. It is very light on details; basically a title and one run-on sentence. So wide in scope you could drive a truck through it, but let’s pull…
-
340B, Biosimilars, Caught my eye, CMMI, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit ManagersCaught my eye — 3/14/25
Read more: Caught my eye — 3/14/25With the exception of the ending of demos/models at the Centers for Medicare & Medicaid Innovation (CMMI), most of the news kind of rolled over me this week. So, instead, here is a capture of what is rattling around my chamber of health policy worries. Who’s on first? What’s on second? I don’t know ……
-
Affordable Care Act, Caught my eye, Cell and Gene, CMMI, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit ManagersCaught my eye — 2/7/25
Read more: Caught my eye — 2/7/25In the DC area, with many family, friends and neighbors working for the federal government, these last few weeks have felt downright crappy. Furloughs, contracts being upended, fear about what’s next — all for people who love their jobs serving the public. It isn’t a fork in the road, it feels like a game of…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Healthcare Costs, Obesity, Pharmacy Benefit ManagersCaught my eye — 9/27/24
Read more: Caught my eye — 9/27/24If you haven’t trained your teams on Medicare Part D changes for 2025, hop to it. Or reach out to me. These are January 1 issues and we’re about to hit October…. Let me clear my throat. The STAT news breaking news headline read “Sanders says pharmacy benefit managers (PBMs) won’t penalize Novo for cutting…
Latest news
- AMP is WAC — 03/13/26
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
Categories
- 340B (63)
- Affordable Care Act (22)
- Alzheimer's (11)
- Biosimilars (32)
- Caught my eye (101)
- Cell and Gene (6)
- Chevron Deference (2)
- CMMI (27)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (7)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (68)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (77)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (27)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)